These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 37032089)
1. Non-operative Management of Spontaneous Gastropleural Fistula Caused by Primary Gastric Diffuse Large B-cell Lymphoma. Suzaki K; Kobayashi M; Kosugi N Intern Med; 2023 Nov; 62(21):3237-3240. PubMed ID: 37032089 [TBL] [Abstract][Full Text] [Related]
2. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy. Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522 [TBL] [Abstract][Full Text] [Related]
3. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. Kang HJ; Lee HH; Jung SE; Park KS; O JH; Jeon YW; Choi BO; Cho SG PLoS One; 2020; 15(9):e0238807. PubMed ID: 32960887 [TBL] [Abstract][Full Text] [Related]
4. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma. Tian C; Chen Z; Li Y J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971 [TBL] [Abstract][Full Text] [Related]
5. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202 [TBL] [Abstract][Full Text] [Related]
6. Rare malignant ulcer related to primary intestinal diffuse large B-cell lymphoma: A case report. Jia N; Tang Y; Li Y Medicine (Baltimore); 2020 Feb; 99(6):e18590. PubMed ID: 32028388 [TBL] [Abstract][Full Text] [Related]
7. Primary breast lymphoma - a case report. Rajabto W; Angkasa YK; Harahap AS; Ham MF; Brahma B Klin Onkol; 2021; 34(6):477-480. PubMed ID: 34911334 [TBL] [Abstract][Full Text] [Related]
8. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147 [TBL] [Abstract][Full Text] [Related]
9. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial. Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150 [TBL] [Abstract][Full Text] [Related]
12. Successful multidisciplinary management of an asymptomatic gastrosplenic fistula in a diffuse large B cell lymphoma patient. Mansouri S; Assane C; Malo FC BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35256358 [TBL] [Abstract][Full Text] [Related]
13. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057 [TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of R-CHOP without splenectomy in stage I primary splenic diffuse large B-cell lymphoma. Rajendran T; Kini JR; Abna A; Prasad K BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 34983812 [TBL] [Abstract][Full Text] [Related]
16. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ; Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632 [TBL] [Abstract][Full Text] [Related]
17. Synchronous gastric cancer and primary lymphoma of right adrenal gland: a case report. Fukuda S; Wakasa T; Hanamoto H; Koyama T; Ohta Y; Inoue M; Terashita D; Gakuhara A; Tomihara H; Ohta K; Kitani K; Hashimoto K; Ishikawa H; Hida JI; Kimura Y Clin J Gastroenterol; 2021 Oct; 14(5):1350-1357. PubMed ID: 34283402 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110 [TBL] [Abstract][Full Text] [Related]
19. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868 [TBL] [Abstract][Full Text] [Related]
20. Successful Treatment of Diffuse Large B-cell Lymphoma Involving Multiple Renal and Bone Infiltrations Presenting with Giant Cell Arteritis-like Manifestations. Yokota K; Morimoto K; Yazawa H; Tsuzuki Wada T; Sakamoto T; Terui Y; Kaneko S; Inoue T; Okada H; Akiyama Y; Mimura T Intern Med; 2024 Jun; 63(11):1645-1652. PubMed ID: 37952957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]